


01-03-07

1FW 1642

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL  
FORM

Use for all correspondence after initial filing)

Total Number of Pages in This Submission

8

Application Number

10/529,163

Filing Date

12/19/2005

First Named Inventor

Diamandis et al.

Art Unit

1642

Examiner Name

L. Goddard

Attorney Docket Number

MTS15USA

## ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/  
Incomplete Application☐Reply to Missing Parts  
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a  
Provisional Application☐Power of Attorney, Revocation  
Change of Correspondence Address☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) \_\_\_\_\_

☐

Landscape Table on CD

☐

After Allowance Communication to TC

☐Appeal Communication to Board  
of Appeals and Interferences☐Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☐Other Enclosure(s) (please identify  
below):

## Remarks

Express Mail No. EO 928 922 596 US  
Customer No. 00270

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Howson &amp; Howson

Signature

Mary E. Bak

Printed name

Mary E. Bak

Date

12/29/2006

Reg. No.

31,215

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



MTS15USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/529,163 Confirmation No.: 6566  
Applicant : Diamandis  
Filed : December 19, 2005  
TC/A.U. : 1642  
Examiner : L. Goddard  
Customer No. : 00270  
Title : METHODS FOR DETECTING ENDOCRINE CANCER

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SECOND INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicant submits to the Examiner the attached document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. The forms are attached and copies of the document are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application, but before the receipt of a first Office Action. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Express Mail No. EO 928 922 596 US



MTS15USA

**REMARKS**

Listed below are co-pending, US patent applications. These applications and the present application are commonly owned:

US Patent Appln Number	US Filing Date	PCT Patent Publication Number	PCT Publication Date	US Patent Number or US Patent Application Publication Number	US Publication Date
09/936,271	September 10, 2001	WO-2000/053776	September 14, 2000	US-7,022,497	April 4, 2006
11/319,952	December 28, 2005			US-2006/134114	June 22, 2006
10/344,394	August 1, 2003	WO-2002/014485	February 2, 2002	US-2004/0058342	March 25, 2004
10/415,222	November 5, 2003	WO-2002/037112	May 10, 2002	US-2004/0115745	June 17, 2004
10/399,013	November 18, 2003	WO-2002/035232	May 2, 2002	US-2004/0096915	May 20, 2004
10/036,308	October 26, 2001			US-2002/0182644 US-6,962,793	December 5, 2002 November 8, 2005
10/478,333	November 21, 2003	WO-2002/097438	December 5, 2002	US-2004/0203012	October 14, 2004
10/492,740	September 13, 2004	WO-2003/033731	April 24, 2003	US-2005/0176002	August 11, 2005
10/510,321	May 25, 2005	WO-2003/085404	October 16, 2003	US-2005/0287528	December 29, 2005
10/526,111	September 20, 2005	WO-2004/021009	March 11, 2004	US-2006/0159616	July 20, 2006
10/526,029	November 22, 2005	WO-2004/021008	March 11, 2004	US-2006/0073525	April 6, 2006
10/529,088	August 4, 2006	WO-2004/029616	April 8, 2004	US-2006/0269971	November 30, 2006
10/544,944	January 26, 2006	WO-2004/075713	September 10, 2004	US-2006/0134120	June 22, 2006
10/546,435	January 26, 2006	WO-2004/077060	September 10, 2004	US-2006/0141471	June 29, 2006
10/868,490	June 14, 2004			US-2005/0106586	May 19, 2005

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached forms during the course of examination of this application.

Respectfully submitted,

HOWSON & HOWSON  
Attorneys for Applicants

By: Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Suite 210  
501 Office Center Drive  
Fort Washington, PA 19034  
Telephone: 215-540-9200  
Telefacsimile: 215-540-5818

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Sheet 1 of 5

**Complete if Known**

Application Number	10/529,163
Filing Date	December 19, 2005
First Named Inventor	Diamandis
Art Unit	1642
Examiner Name	L. Goddard
Attorney Docket Number	MTS15USA

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-7,022,497	04-04-2006	Yousef et al.	
	AB	US-6,962,793	11-08-2005	Diamandis	
	AC	US-2006/134114	02-22-2006	Yousef et al.	
	AD	US-2004/0058342	03-25-2004	Yousef et al.	
	AE	US-2004/0115745	06-17-2004	Diamandis et al.	
	AF	US-2004/0096915	05-20-2004	Diamandis	
	AG	US-2002/0182644	12-05-2002	Diamandis	
	AH	US-2004/0203012	10-14-2004	Diamandis	
	AI	US-2005/0176002	08-11-2005	Diamandis et al.	
	AJ	US-2005/0287528	12-29-2005	Diamandis et al.	
	AAA	US-2006/0159616	07-20-2006	Yousef et al.	
	AAB	US-2006/0073525	04-06-2006	Yousef et al.	
	AAC	US-2006/0269971	11-30-2006	Diamandis	
	AAD	US-2006/0134120	06-22-2006	Diamandis	
	AAE	US-2006/0141471	06-29-2006	Diamandis et al.	
	AAF	US-2005/0106586	05-19-2005	Diamandis	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/529,163
				Filing Date	December 19, 2005
				First Named Inventor	Diamandis
				Art Unit	1642
				Examiner Name	L. Goddard
Sheet	2	of	5	Attorney Docket Number	MTS15USA

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	AL	WO-2000/053776	09-14-2000	Yousef et al.		
	AM	WO-2002/014485	02-02-2002	Yousef et al.		
	AN	WO-2002/035232	05-02-2002	Diamandis		
	AO	WO-2002/097438	12-05-2002	Diamandis		
	AP	WO-2003/033731	04-24-2003	Diamandis et al.		
	AQ	WO-2003/085404	10-16-2003	Diamandis et al.		
	AAL	WO-2004/021009	03-11-2004	Yousef et al.		
	AAM	WO-2004/021008	03-11-2004	Diamandis et al.		
	AAN	WO-2004/029616	04-09-2004	Diamandis		
	AAO	WO-2004/075713	09-10-2004	Diamandis		
	AAP	WO-2004/077060	09-10-2004	Diamandis et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Substitute for form 1449/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/529,163
				Filing Date	December 19, 2005
				First Named Inventor	Diamandis
				Art Unit	1642
				Examiner Name	L. Goddard
				Attorney Docket Number	MTS15USA
Sheet	3	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR	ANISOWICZ et al., "A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer", Mol. Med., 2:624-636 (September 1996)	
	AS	DHAR et al., "Analysis of Normal Epithelial Cell Specific-1 (NES1)/Kallikrein 10 mRNA Expression by in situ Hybridization, a Novel Marker for Breast Cancer", Clin. Cancer Res., 7:3393-3398 (November 2001)	
	AT	DIAMANDIS et al., "New Nomenclature for the Human Tissue Kallikrein Gene Family", Clin. Chem., 46:1855-1858 (November 2000)	
	AU	DIAMANDIS et al., "Human Kallikrein 6 (Zyme/Protease M/Neurosin): A New Serum Biomarker of Ovarian Carcinoma", Clin. Biochem., 33:579-583 (October 2000)	
	AV	DIAMANDIS et al., "Human Kallikrein 11: A New Biomarker of Prostate and Ovarian Cancer", Cancer Res., 62:295-300 (January 1, 2002)	
	AW	DIAMANDIS et al., "Human Tissue Kallikrein Gene Family: A Rich Source of Novel Disease Biomarkers", Expert Rev. Mol. Diagn., 1:182-190 (July 2001)	
	AX	GREENLEE et al., "Cancer Statistics, 2001", CA Cancer J. Clin., 51:15-36 (January/February 2001)	
	AY	HOLSCHNEIDER et al., "Ovarian Cancer: Epidemiology, Biology and Prognostic Factors", Semin. Surg. Oncol., 19:3-10 (July-August 2000)	
	AZ	HOOPER et al., "Identification and Characterization of KLK14, A Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle", Genomics, 73:117-122 (April 1, 2001)	
	AAR	KIM et al., "Human Kallikrein Gene 5 (KLK5) Expression in an Indicator of Poor Prognosis in Ovarian Cancer", Br. J. Cancer, 84:643-650 (March 2, 2001)	
	AAS	LAMBERT-MESSERLIAN, "Is Inhibin a Serum Marker for Ovarian Cancer?", Eur. J. Endocrinol., 142:331-333 (April, 2000)	
	AAT	LUO et al., "Human Kallikrein 10: A Novel Tumor Marker for Ovarian Carcinoma", Clin. Chim. Acta, 306:111-118 (April 2001)	
	AAU	LUO et al., "Expression of the Normal Epithelial Cell-Specific 1 (NES-1; KLK10) Candidate Tumour Suppressor Gene in Normal and Malignant Testicular Tissue", Brit. J. Cancer., 85:220-224 (July 20, 2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/529,163
				Filing Date	December 19, 2005
				First Named Inventor	Diamandis
				Art Unit	1642
				Examiner Name	L. Goddard
Sheet	4	of	5	Attorney Docket Number	MTS15USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AAV	MAGKLARA et al., "The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and Its Prognostic Value in Ovarian Cancer", Clin. Cancer Res., 7:806-811 (April 2001)	
	AAW	MENON et al., "Recent Developments in Ovarian Cancer Screening", Cur. Opin. Obstet. Gynecol., 12:39-42 (February 2000)	
	AAX	MEYER et al., "Role of Tumour Markers in Monitoring Epithelial Ovarian Cancer", Br. J. Cancer, 82:1535-1538 (May 2000)	
	AAY	MOK et al., "Prostasin: A Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology", J. Natl. Cancer Inst., 93:1458-1464 (October 3, 2001)	
	AAZ	RITTENHOUSE et al., "Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate", Crit. Rev. Clin. Lab. Sci., 35:275-368 (August 1998)	
	BR	TAKAYAMA et al., "Activation of Prostate-Specific Antigen Precursor (pro-PSA) by Prostins, a Novel Human Prostatic Serine Protease Identified by Degenerate PCR", Biochemistry, 40:1679-1687 (February 13, 2001)	
	BS	TANIMOTO et al., "The Stratum Corneum Chymotryptic Enzyme that Mediates Shedding and Desquamation of Skin Cells in Highly Overexpressed in Ovarian Tumour Cells", Cancer, 86:2074-2082 (November 15, 1999)	
	BT	WOOLAS ET AL., "Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses", Gynecol. Oncol., 59:111-116 (October 1995)	
	BU	XU et al., "OVX1 Radioimmunoassay Complements CA-125 for Predicting the Presence of Residual Ovarian Carcinoma at Second-Look Surgical Surveillance Procedures", J. Clin. Oncol., 11:1506-1510 (August 1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/529,163	
			Filing Date	December 19, 2005	
			First Named Inventor	Diamandis	
			Art Unit	1642	
			Examiner Name	L. Goddard	
Sheet	5	of	5	Attorney Docket Number	MTS15USA

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	BV	YOUSEF et al., "The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease". Endocr. Rev., 22:184-204 (April, 2001)		
	BW	YOUSEF et al., "Genomic Organization of the Human Kallikrein Gene Family on Chromosome 19q13.3-q13.4", Biochem Biophys. Res. Commun., 276:125-133 (September 16, 2000)		
	BX	YOUSEF et al., "Molecular Cloning of the Human Kallikrein 15 Gene (KLK15)", J. Biol. Chem., 276:53-61 (January 5, 2001)		
	BY	YOUSEF et al., "Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker", Cancer Res., 61:7811-7818 (November 1, 2001)		
	BZ	YOUSEF et al., "Cloning of a New Member of the Human Kallikrein Gene Family, KLK14, Which is Down-Regulated in Different Malignancies", Cancer Res., 61:3425-3431 (April 15, 2001)		
	BBR	YOUSEF et al., "Identification and Characterization of KLK-L4, A New Kallikrein-Like Gene that Appears to be Down-Regulated in Breast Cancer Tissues", J. Biol. Chem., 275:11891-11898 (April 21, 2000)		
	BBS	Genbank Accession No. AAF06065, submitted November 1, 1999		
	BBT	Genbank Accession No. AAD26426, submitted November 1, 1999		
	BBU	Genbank Accession No. AAF06066, submitted November 1, 1999		
	BBV	Genbank Accession No. AAK48524, submitted June 30, 2000		
	BBW	Genbank Accession No. AAD50773, submitted June 21, 1999		
	BBX	Genbank Accession No. AAG09469, submitted March 6, 2000		
	BBY	Genbank Accession No. AAG09472, submitted March 6, 2000		
	BBZ	Genbank Accession No. AAG09471, submitted March 6, 2000		
	CR	Genbank Accession No. AAG09470, submitted March 6, 2000		

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.